Showing results (411-420 of 528) with videos related to

Sort By:
Pageof 53
Journal of Neurochemistry|August 21, 2018
Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin studyBrit Mollenhauer, Frederick DuBois Bowman, Daniel Drake, et al.
Annals of Clinical and Translational Neurology|April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined SynucleinopathyDaniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 4, 2025
A Novel α-Synuclein K58N Missense Variant in a Patient with Parkinson's DiseaseMohammed Al-Azzani, Sandrina Weber, Nagendran Ramalingam, et al.
Medrxiv : the Preprint Server for Health Sciences|February 24, 2025
A novel alpha-synuclein K58N missense variant in a patient with Parkinson's diseaseMohammed Al-Azzani, Sandrina Weber, Nagendran Ramalingam, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 25, 2018
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative CohortTanya Simuni, Andrew Siderowf, Shirley Lasch, et al.
Journal of Parkinson'S Disease|October 3, 2025
Quantitative measurements of α-synuclein seeds in CSF inform diagnosis of synucleinopathiesIlham Y Abdi, Indulekha P Sudhakaran, Simona S Ghanem, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
European Journal of Human Genetics : EJHG|January 22, 2015
Rare variants in β-Amyloid precursor protein (APP) and Parkinson's diseaseEva C Schulte, Akio Fukumori, Brit Mollenhauer, et al.
The Lancet. Neurology|November 4, 2019
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional studyTanya Simuni, Liz Uribe, Hyunkeun Ryan Cho, et al.
Pageof 53